Celebrex Short Versus Long Therapy In Osteoarthritis Of The Knee

• Status: Completed
• Trial end date: 2006-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase III, multicentre, randomized, double blind, parallel-group, pilot study designed to compare a long term (12 weeks) versus a short term (2 weeks) treatment with celecoxib 200 mg/die in treatment and prevention of new flare in patients with osteoarthritis of the knee.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Celecoxib

Criteria

Inclusion Criteria:

• diagnosis of OA of the knee according to the ACR Classification Criteria for osteoarthritis;

• patients in flare

Exclusion Criteria:

• any concomitant inflammatory rheumatic condition which may interfere with the assessment of OA

• clinical or radiological evidence of chondrocalcinosis